Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SPC005
MIFTS: 44

Speech Disorder

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Speech Disorder

About this section

MalaCards integrated aliases for Speech Disorder:

Name: Speech Disorder 12 15
Speech Disorders 55 44 73

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:92
MeSH 44 D013064
NCIt 50 C5041
ICD10 33 R47
UMLS 73 C0037822
Sources

Summaries for Speech Disorder

About this section
Disease Ontology : 12 A communication disorder that involves difficulty with the act of speech production.

MalaCards based summary : Speech Disorder, also known as speech disorders, is related to epilepsy, focal, with speech disorder and with or without mental retardation and mutism, and has symptoms including scanning speech, aprosodia and other and unspecified speech disturbances. An important gene associated with Speech Disorder is GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A), and among its related pathways/superpathways are Lysosome and Nicotine addiction. The drugs Memantine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, tongue and testes, and related phenotype is behavior/neurological.

Wikipedia : 76 Speech disorders or speech impediments are a type of communication disorder where ''normal'' speech is... more...

Sources

Related Diseases for Speech Disorder

About this section

Diseases related to Speech Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 epilepsy, focal, with speech disorder and with or without mental retardation 33.8 GRIN2A GRIN2B LOC105371077
2 mutism 31.6 CNTNAP2 GRN
3 stuttering 31.2 CNTNAP2 FOXP2 GNPTAB GNPTG NAGPA
4 speech and communication disorders 30.0 CNTNAP2 FOXP1 FOXP2 GNPTG GRIN2A GRN
5 articulation disorder 29.7 CNTNAP2 FOXP2 GNPTAB GNPTG NAGPA PHF21A
6 aphasia 29.6 FOXP2 GRIN2A GRN
7 autism 29.4 CNTNAP2 FOXP2 GRIN2A GRIN2B
8 grin2a-related speech disorders and epilepsy 12.2
9 epilepsy-aphasia spectrum 11.3
10 spondyloepiphyseal dysplasia-brachydactyly and distinctive speech 11.1
11 intellectual deficit buenos-aires type 11.0
12 neurodegeneration with brain iron accumulation 1 10.8
13 centralopathic epilepsy 10.6
14 spastic paraplegia 20, autosomal recessive 10.6
15 pontine tegmental cap dysplasia 10.6
16 echolalia 10.6
17 bile acid synthesis defect, congenital, 1 10.2 GRIN2A GRIN2B
18 mucolipidosis iii alpha/beta 10.2 GNPTAB GNPTG
19 inclusion-cell disease 10.2 GNPTAB GNPTG
20 mucolipidosis ii alpha/beta 10.2 GNPTAB GNPTG
21 fetal alcohol spectrum disorder 10.1 GRIN2A GRIN2B
22 cleft palate, isolated 10.1
23 ocular dominance 10.1 GRIN2A GRIN2B
24 fetal alcohol syndrome 10.1 GRIN2A GRIN2B
25 schizophrenia 10.1
26 cerebral palsy 10.1
27 d-2-hydroxyglutaric aciduria 1 10.1 GRIN2A GRIN2B
28 reading disorder 10.1 CNTNAP2 FOXP2
29 childhood apraxia of speech 10.0 CNTNAP2 FOXP2
30 valproate embryopathy 10.0 GRIN2A GRIN2B
31 focal epilepsy 10.0 CNTNAP2 GRIN2A GRIN2B
32 benign epilepsy with centrotemporal spikes 10.0 CNTNAP2 FOXP2 GRIN2A
33 autism spectrum disorder 10.0 CNTNAP2 FOXP2 GRIN2B
34 disease of mental health 9.9 GRIN2A GRIN2B GRN
35 specific language impairment 9.9 CNTNAP2 FOXP2
36 writing disorder 9.9 GRN SLC17A5
37 down syndrome 9.9
38 supranuclear palsy, progressive, 1 9.9
39 brain injury 9.9
40 traumatic brain injury 9.9
41 microcephaly 9.9
42 epilepsy 9.9
43 cleft lip 9.9
44 dysphagia 9.9
45 cleft lip/palate 9.9
46 dyslexia 9.9 FOXP2 GNPTAB GNPTG GRIN2B NAGPA
47 amyotrophic lateral sclerosis 1 9.7
48 ankyloglossia 9.7
49 multiple system atrophy 1 9.7
50 treacher collins syndrome 1 9.7

Graphical network of the top 20 diseases related to Speech Disorder:



Diseases related to Speech Disorder
Sources

Symptoms & Phenotypes for Speech Disorder

About this section

UMLS symptoms related to Speech Disorder:


scanning speech, aprosodia, other and unspecified speech disturbances, other speech disturbances, cluttering, dysglossia, rhinolalia

MGI Mouse Phenotypes related to Speech Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.23 CNTNAP2 GNPTAB GRIN2A GRIN2B GRN PHF21A
Sources

Drugs & Therapeutics for Speech Disorder

About this section

Drugs for Speech Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
2
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
3
Natalizumab Approved, Investigational Phase 4 189261-10-7
4
Donepezil Approved Phase 4 120014-06-4 3152
5
Levodopa Approved Phase 4,Phase 2,Phase 3,Not Applicable 59-92-7 6047
6
Citalopram Approved Phase 4 59729-33-8 2771
7
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
8 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Not Applicable
10 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
11 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
12 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable
13 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
15 Sympathomimetics Phase 4,Phase 2,Not Applicable
16 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
17 Cardiotonic Agents Phase 4,Phase 2,Not Applicable
18 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
20 Cholinesterase Inhibitors Phase 4,Phase 2,Not Applicable
21 Cholinergic Agents Phase 4,Phase 2,Not Applicable
22 Nootropic Agents Phase 4,Phase 2,Phase 1,Not Applicable
23 Dopamine agonists Phase 4,Not Applicable
24 Neurotransmitter Uptake Inhibitors Phase 4,Not Applicable
25 Antidepressive Agents, Second-Generation Phase 4,Not Applicable
26 Antidepressive Agents Phase 4,Phase 1,Phase 2,Not Applicable
27 Serotonin Uptake Inhibitors Phase 4
28 Serotonin Agents Phase 4
29 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Early Phase 1
30 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1
31 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
32 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
33
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 50-67-9 5202
34
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359 38101
35
Miglustat Approved Phase 3,Phase 1 72599-27-0 51634
36 tannic acid Approved Phase 3,Not Applicable
37
Benzocaine Approved, Investigational Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
38
Methylene blue Approved, Investigational Phase 3 61-73-4
39
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Phase 3,Early Phase 1 2921-57-5
40
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 6055-19-2, 50-18-0 2907
41
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Early Phase 1 83-43-2 6741
42
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Early Phase 1 50-24-8 5755
43
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 3,Early Phase 1 302-25-0
44
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
45
Tenecteplase Approved Phase 3,Phase 2 191588-94-0
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
48
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
49
Clopidogrel Approved Phase 3 113665-84-2, 120202-66-6 60606
50
Asenapine Approved Phase 3 65576-45-6, 85650-56-2 3001386

Interventional clinical trials:

(show top 50) (show all 375)
# Name Status NCT ID Phase Drugs
1 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
2 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT02142205 Phase 4
3 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
4 Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Completed NCT00196690 Phase 4 Donepezil
5 Dopaminergic Enhancement of Learning and Memory in Aphasia Completed NCT00102869 Phase 4 levodopa
6 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
7 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
8 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
9 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
10 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
11 Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). Unknown status NCT02909088 Phase 2, Phase 3 Ecopipam 50mg;Ecopipam 100mg
12 Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients Unknown status NCT02241213 Phase 3
13 Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation Unknown status NCT00822068 Phase 2, Phase 3
14 Randomized Clinical Trial of Phonological Interventions Unknown status NCT00818428 Phase 2, Phase 3
15 AM-111 in the Treatment of Acute Inner Ear Hearing Loss Completed NCT02561091 Phase 3 AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
16 Augmenting Language Therapy for Aphasia: Levodopa Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
17 A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering Completed NCT00830154 Phase 2, Phase 3 pagoclone
18 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
19 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
20 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
21 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
22 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion Recruiting NCT02398656 Phase 3 Tenecteplase;Antiplatelet treatment
23 Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia Recruiting NCT00903266 Phase 3
24 The Healthy Patterns Study Recruiting NCT03682185 Phase 3
25 Use of Local Intraoperative Steroid in MIS TLIF Active, not recruiting NCT03308084 Phase 3 Methylprednisolone;Dexamethasone
26 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
27 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
28 Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy Not yet recruiting NCT03676439 Phase 2, Phase 3
29 A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering Suspended NCT01684657 Phase 3 Asenapine
30 Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma Terminated NCT02111785 Phase 2, Phase 3 Dexamethasone
31 Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment Terminated NCT02809118 Phase 3 AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
32 Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia Terminated NCT01277575 Phase 3
33 Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Terminated NCT02245568 Phase 3 TRx0237
34 Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study Unknown status NCT02540109 Phase 2
35 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS) Unknown status NCT01924702 Phase 2
36 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation Unknown status NCT01221779 Phase 2
37 Follow-up of Children After Stuttering Treatment Unknown status NCT00709072 Phase 2
38 Spacing Lidcombe Program Clinic Visits Unknown status NCT00680303 Phase 2
39 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations Unknown status NCT02676843 Phase 2 18F-AV-1451
40 Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
41 Effects of Tolcapone on Frontotemporal Dementia Unknown status NCT00604591 Phase 2 Tolcapone;Placebo
42 Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients Completed NCT01255358 Phase 2 Dexamethasone
43 TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion Completed NCT01654445 Phase 2 Tenecteplase
44 Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia Completed NCT00824512 Phase 2 EGb 761 120 mg;Placebo
45 Long-Term Assessment of Remyelinating Therapy Completed NCT02657915 Phase 2 Placebo;BIIB033 100mg/Kg
46 Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Completed NCT00977665 Phase 2 rasagiline mesylate;placebo
47 Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
48 Randomised Controlled Treatment Study of Selective Mutism Completed NCT01002196 Phase 2
49 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
50 Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS) Completed NCT00239915 Phase 2 Pagoclone

Search NIH Clinical Center for Speech Disorder

Cochrane evidence based reviews: speech disorders

Sources

Genetic Tests for Speech Disorder

About this section
Sources

Anatomical Context for Speech Disorder

About this section

MalaCards organs/tissues related to Speech Disorder:

41
Brain, Tongue, Testes, Cortex, Liver, Tonsil
Sources

Publications for Speech Disorder

About this section

Articles related to Speech Disorder:

(show top 50) (show all 350)
# Title Authors Year
1
Use of electropalatography in the treatment of speech disorders in children with Down syndrome: a randomized controlled trial. ( 30039902 )
2018
2
Dualistic effect of pallidal deep brain stimulation on motor speech disorders in dystonia. ( 29576500 )
2018
3
Aminoglycoside-associated nonsyndromic deafness and speech disorder in mitochondrial A1555G mutation in a family: A case report. ( 30335006 )
2018
4
Estimates of the Prevalence of Speech and Motor Speech Disorders in Youth With 22q11.2 Deletion Syndrome. ( 30515510 )
2018
5
Relations between Sensorimotor Integration and Speech Disorders in Parkinson's Disease. ( 28847285 )
2018
6
A Brain Marker for Developmental Speech Disorders. ( 29705112 )
2018
7
Mobile apps for treatment of speech disorders in children: An evidence-based analysis of quality and efficacy. ( 30092095 )
2018
8
Speech disorders in Parkinson's disease: pathophysiology, medical management and surgical approaches. ( 30223711 )
2018
9
Phonological and phonetic studies of speech disorders across languages - in honour of Martin J. Ball. ( 30382005 )
2018
10
Identification of a novel homozygous TRAPPC9 gene mutation causing non-syndromic intellectual disability, speech disorder, and secondary microcephaly. ( 29031008 )
2017
11
Two unrelated children with overlapping 6q25.3 deletions, motor speech disorders, and language delays. ( 28767196 )
2017
12
Changes in White Matter Integrity following Intensive Voice Treatment (LSVT LOUD®) in Children with Cerebral Palsy and Motor Speech Disorders. ( 28750368 )
2017
13
Intensive treatment of speech disorders in robin sequence: a case report. ( 29069271 )
2017
14
Longitudinal follow-up to evaluate speech disorders in early-treated patients with infantile-onset Pompe disease. ( 28039015 )
2017
15
Speech disorders in Parkinson's disease: early diagnostics and effects of medication and brain stimulation. ( 28101650 )
2017
16
Toward a Measure of Communicative Participation for Children with Developmental Speech Disorders. ( 28618441 )
2017
17
Effects of a Conversation-Based Intervention on the Linguistic Skills of Children With Motor Speech Disorders Who Use Augmentative and Alternative Communication. ( 28672283 )
2017
18
Analysis of a distinct speech disorder seen in chronic manganese toxicity following Ephedrone abuse. ( 27310289 )
2016
19
Asthma, hay fever and food allergy are associated with caregiver-reported speech disorders in US children. ( 27091599 )
2016
20
Feasibility of Technology Enabled Speech Disorder Screening. ( 27440284 )
2016
21
Neurophysiologic markers of primary motor cortex for laryngeal muscles and premotor cortex in caudal opercular part of inferior frontal gyrus investigated in motor speech disorder: a navigated transcranial magnetic stimulation (TMS) study. ( 27130564 )
2016
22
Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients. ( 26843071 )
2016
23
Speech disorders did not correlate with age at onset of Parkinson's disease. ( 26982988 )
2016
24
A systematic review of treatment intensity in speech disorders. ( 27063688 )
2016
25
Motor Speech Disorders: Where Will We Be in 10 Years? ( 27232096 )
2016
26
Functional speech disorders: clinical manifestations, diagnosis, and management. ( 27719858 )
2016
27
The Atlanta Motor Speech Disorders Corpus: Motivation, Development, and Utility. ( 27736811 )
2016
28
Spatial distribution and the prevalence of speech disorders in the provinces of Iran. ( 27974915 )
2016
29
Sensorimotor speech disorders in Parkinson's disease: Programming and execution deficits. ( 29213457 )
2016
30
Eczema Is Associated with Childhood Speech Disorder: A Retrospective Analysis from the National Survey of Children's Health and the National Health Interview Survey. ( 26520915 )
2015
31
Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. ( 25683763 )
2015
32
Psychogenic speech disorder--a case report. ( 26417806 )
2015
33
Motor speech treatment protocol for developmental motor speech disorders. ( 24088085 )
2015
34
Functional MRI evidence for fine motor praxis dysfunction in children with persistent speech disorders. ( 25481413 )
2015
35
Evidence-based treatment of voice and speech disorders in Parkinson disease. ( 25943966 )
2015
36
The impact of demographic and socio-economic conditions on the prevalence of speech disorders in preschool children in Bitola. ( 26012126 )
2015
37
Changes of some functional speech disorders after surgical correction of skeletal anterior open bite. ( 26164798 )
2015
38
The use of non-speech oral-motor exercises among Indian speech-language pathologists to treat speech disorders: An online survey. ( 26304211 )
2015
39
Orofacial Praxis Abilities in Children with Speech Disorders. ( 26491472 )
2015
40
Spatial distribution and the prevalence of speech disorders in the provinces of Iran. ( 28255406 )
2015
41
Motor Speech Disorders Associated with Primary Progressive Aphasia. ( 25309017 )
2014
42
Detection of chromosomal breakpoints in patients with developmental delay and speech disorders. ( 24603971 )
2014
43
Effectiveness of tongue-tie division for speech disorder in children. ( 25142274 )
2014
44
Vowel acoustics in dysarthria: speech disorder diagnosis and classification. ( 24687467 )
2014
45
Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes. ( 25348587 )
2014
46
Can peripheral hearing justify the speech disorders in children with operated cleft palate? ( 25992059 )
2014
47
Correlation of otologic complaints in soldiers with speech disorders after traumatic brain injury. ( 24275459 )
2014
48
Auditory-motor interactions in pediatric motor speech disorders: neurocomputational modeling of disordered development. ( 24491630 )
2014
49
Multi-sensory treatment for children with developmental motor speech disorders. ( 24617702 )
2014
50
Park Play: a picture description task for assessing childhood motor speech disorders. ( 24665912 )
2014
Sources

Variations for Speech Disorder

About this section
Sources

Expression for Speech Disorder

About this section
Search GEO for disease gene expression data for Speech Disorder.
Sources

Pathways for Speech Disorder

About this section

Pathways related to Speech Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Lysosome 37
11.01 GNPTAB GNPTG NAGPA SLC17A5
2
Nicotine addiction 37
10.92 GRIN2A GRIN2B
3
nNOS Signaling at Neuronal Synapses 64
10.72 GRIN2A GRIN2B
4
Reelin signaling pathway 1
10.62 GRIN2A GRIN2B
5
SALM protein interactions at the synapses 66
10.28 GRIN2A GRIN2B
Sources

GO Terms for Speech Disorder

About this section

Cellular components related to Speech Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synaptic membrane GO:0097060 9.16 GRIN2A GRIN2B
2 postsynaptic density membrane GO:0098839 8.96 GRIN2A GRIN2B
3 NMDA selective glutamate receptor complex GO:0017146 8.62 GRIN2A GRIN2B

Biological processes related to Speech Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cerebral cortex development GO:0021987 9.5 CNTNAP2 FOXP2 TRAPPC9
2 lysosome organization GO:0007040 9.48 GNPTAB NAGPA
3 carbohydrate phosphorylation GO:0046835 9.46 GNPTAB GNPTG
4 ionotropic glutamate receptor signaling pathway GO:0035235 9.43 GRIN2A GRIN2B
5 glutamate receptor signaling pathway GO:0007215 9.4 GRIN2A GRIN2B
6 excitatory chemical synaptic transmission GO:0098976 9.37 GRIN2A GRIN2B
7 calcium ion transmembrane import into cytosol GO:0097553 9.26 GRIN2A GRIN2B
8 vocal learning GO:0042297 9.16 CNTNAP2 FOXP2
9 secretion of lysosomal enzymes GO:0033299 8.96 GNPTAB NAGPA
10 N-glycan processing to lysosome GO:0016256 8.62 GNPTAB GNPTG

Molecular functions related to Speech Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 androgen receptor binding GO:0050681 9.32 FOXP1 FOXP2
2 ionotropic glutamate receptor activity GO:0004970 9.26 GRIN2A GRIN2B
3 NMDA glutamate receptor activity GO:0004972 9.16 GRIN2A GRIN2B
4 glutamate-gated calcium ion channel activity GO:0022849 8.96 GRIN2A GRIN2B
5 UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity GO:0003976 8.62 GNPTAB GNPTG
Sources

Sources for Speech Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....